To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
All the news of the Institute of life sciences Frédéric Joliot
Nature is full of substances that have evolved over millions of years to provide useful properties for human well-being. Coming from complex and rare environments, these molecules are difficult to identify. We have developed specific strategies to explore and exploit this natural resource in order to identify potential drug candidates. We have optimized the classical strategy consisting in deconvolution cycles of venoms fractions and screening on selected targets. We have also developed the Venomics strategy based on the identification by transcriptomic/proteomic approaches of original toxins sequences that can be produced by recombinant expression or solid-phase peptide synthesis and screen on relevant molecular targets. These two screening strategies, combined with a careful identification of therapeutic targets (G protein coupled receptor and ion channels) linked to a clear therapeutic need, allow us to identify new molecules with interesting pharmacological activities (Reynaud et al., 2020) (Droctove et al., 2020) (Goncalves et al., 2019) (Ciolek et al., 2017).
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.